(Q44105863)

29 November 2017

title

Treatment of nephrotic hyperlipoproteinemia with gemfibrozil (English)

1 reference

29 November 2017

0 references

Groggel GC

1

1 reference

29 November 2017

Cheung AK

series ordinal

2

1 reference

29 November 2017

Ellis-Benigni K

series ordinal

3

1 reference

29 November 2017

Wilson DE

series ordinal

4

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 1989

1 reference

29 November 2017

1 reference

29 November 2017

volume

36

1 reference

29 November 2017

issue

2

1 reference

29 November 2017

page(s)

266-271

1 reference

https://scigraph.springernature.com/pub.10.1038/ki.1989.189

29 November 2017

exact match

0 references

cites work

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Ischaemic heart-disease as a complication of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Does the nephrotic syndrome increase the risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

The nephrotic syndrome and its complications

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Management of the idiopathic nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Chronic clofibrate therapy in maintenance hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Change in composition of high density lipoprotein during gemfibrozil therapy

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Fibric acids: effects on lipids and lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Lipoprotein distribution and composition in the human nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Effect of probucol on hyperlipidemia in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

The effect of renal function on the pharmacokinetics of gemfibrozil

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Hypertriglyceridemia: a contraindication to the use of bile acid binding resins

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.1989.189

7 January 2021

Identifiers

DOI

10.1038/KI.1989.189

1 reference

29 November 2017

1 reference